High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.
about
Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancerIsolated limb perfusion for malignant melanoma: systematic review on effectiveness and safetyInflammatory adverse events are associated with disease-free survival after vaccine therapy among patients with melanoma.Acute-phase response patterns in isolated hepatic perfusion with tumour necrosis factor alpha (TNF-alpha) and melphalan in patients with colorectal liver metastases.Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats.TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects.Low-dose tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats.Nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusionsIsolated limb perfusion for local gene delivery: efficient and targeted adenovirus-mediated gene transfer into soft tissue sarcomas.Pegylated liposomal tumor necrosis factor-alpha results in reduced toxicity and synergistic antitumor activity after systemic administration in combination with liposomal doxorubicin (Doxil) in soft tissue sarcoma-bearing rats.Isolated limb perfusion with actinomycin D and TNF-alpha results in improved tumour response in soft-tissue sarcoma-bearing rats but is accompanied by severe local toxicityLack of cell-cycle specific effects of tumor necrosis factor-alpha on tumor cells in vitro: implications for combination tumor therapy with doxorubicin.Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-alpha-based isolated hepatic perfusionLack of efficacy of Doxil in TNF-alpha-based isolated limb perfusion in sarcoma-bearing rats.One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases.Histamine combined with melphalan in isolated limb perfusion for the treatment of locally advanced soft tissue sarcomas: preclinical studies in rats.Isolated limb perfusion with melphalan and TNF-alpha in the treatment of extremity sarcoma.Analysis of factors influencing outcome in patients with in-transit malignant melanoma undergoing isolated limb perfusion using modern treatment parameters.The major acute-phase protein, serum amyloid P component, in mice is not involved in endogenous resistance against tumor necrosis factor alpha-induced lethal hepatitis, shock, and skin necrosis.Adult soft tissue sarcoma.Isolated hepatic perfusion for patients with liver metastases.Hyporesponsiveness of SPRET/Ei mice to lethal shock induced by tumor necrosis factor and implications for a TNF-based antitumor therapy.Isolated limb perfusion with TNF-alpha and melphalan for distal parts of the limb in soft tissue sarcoma patients.Hyperthermic isolated limb perfusion for extremity soft tissue sarcomas: systematic review of clinical efficacy and quality assessment of reported trials.Selective protection of human liver tissue in TNF-targeting of cancers of the liver by transient depletion of adenosine triphosphate.Isolated limb perfusion for melanoma.Inhibition of establishment and growth of mouse liver metastases after treatment with interferon gamma and beta-1,3-D-glucan.Suppression of tumor angiogenesis through the inhibition of integrin function and signaling in endothelial cells: which side to target?Manipulation of the tumour-associated vasculature to improve tumour therapy.Chemotherapeutic approaches for targeting cell death pathways.Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapySolid tumor therapy: manipulation of the vasculature with TNF.TNF-alpha is critical for ischemia-induced leukostasis, but not retinal neovascularization nor VEGF-induced leakageDissection of stromal and cancer cell-derived signals in melanoma xenografts before and after treatment with DMXAA.Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: three time periods at risk for amputation.Interleukin 1 beta synergises with interleukin 2 in the outgrowth of autologous tumour-reactive CD8+ effectors.Thermal enhancement of both tumour necrosis factor alpha-induced systemic toxicity and tumour cure in ratsChanges in endogenous cytokines, adhesion molecules and platelets during cytokine-induced tumour necrosis.Reduction of interstitial fluid pressure after TNF-alpha treatment of three human melanoma xenografts.ED-B fibronectin as a target for antibody-based cancer treatments.
P2860
Q24563227-BF00511C-A294-47E2-94E2-48457D3AE9E0Q24633360-B631535B-AA87-43BE-AA70-B6878DB742C9Q30370026-BBE7FD7E-FDE0-4C18-88A6-DDD4DC1119CBQ33178477-3059F80E-F8F5-4FE7-89BB-8F321E21F02DQ33178607-D1A3DAB6-A564-418F-92FA-CA7C28BFAFC5Q33180038-044E2504-2D9B-481F-BACF-4F0311682CCCQ33180936-71BB032A-8C30-49FF-BBD0-D8C1F2339200Q33181229-FAE9EED6-224F-49CE-943C-ECFE2AF3606BQ33181472-3961082E-D44F-4D08-975A-5F218338C89BQ33183242-8B0523D7-2E43-458D-8075-F1842BC39D16Q33183585-53EC5BEC-1E5D-44D9-9E39-69A59001B00AQ33183884-70A33A81-D8DF-4858-AB26-334B7D67DE53Q33186209-466EFBC4-E246-4145-AEFA-F9B3D1CD2C23Q33204006-DDE20F77-94FA-406C-B0D9-0D1F90A2AC95Q33209414-1825CB83-024B-4426-A277-D13A5DF88ABEQ33224018-6AA6F3A4-3367-405B-AEEC-1542B50B2D7AQ33309291-A06F4467-F716-4DCC-AFB7-4BC6FC7BF128Q33561919-927D1B36-6D2E-4664-BC20-777CEAB32B07Q33598362-0E1AFF44-F258-454D-A8BB-11DE59C31309Q33649919-9437BA2E-2391-437F-B88F-558045178B0EQ33937362-E20657D2-26D6-4B36-81C5-D4A20A467E6EQ34035198-321C1FE0-8CD0-4CF6-BAC8-A77BDD3E2EBEQ34054797-B1CA8B40-342B-4BC9-998E-6F282627C001Q34340824-779AA8D1-47E9-44AE-8E72-04015BF78A22Q34526187-B2A356BA-4E82-4146-B6C5-0D63608F8D14Q34580517-B79255FF-A630-439F-A56D-61F069B45363Q34747126-0EC2059E-88B7-4078-B81A-52493CCA8A5CQ34966050-F1525990-A75E-443D-86D0-AA5E58B950C9Q35072789-FAC6E682-3F77-41A5-AFC0-4F142BFFB08DQ35094229-00AEDC0C-8402-4695-AF35-DB47BBACF7F1Q35119800-491EAA0B-B194-412F-9EFF-4E1A58DBB15CQ35142322-90105F15-DB65-4418-901D-9219D60425D9Q35642213-75C4293F-84E6-4338-88D0-B58374E3A608Q35832390-CAFF813E-2892-4287-869F-0993950526DEQ35880947-D2E408BC-1CF3-4130-81BE-47FE96A4A01BQ36079678-259F6C1F-4836-4346-9813-009EA125CA31Q36081034-13910BD9-4BBA-468C-8DE4-BE86559B94B2Q36081325-69B37F1A-7C37-41B9-8052-1F1CBE9FDB30Q36135861-109DC5BB-23AF-4E04-A507-C13398A4A028Q36158702-C7F6C67C-BEF2-4807-85B3-2C51ED679F6B
P2860
High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.
description
1992 nî lūn-bûn
@nan
1992 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
High-dose recombinant tumor ne ...... imbs for melanoma and sarcoma.
@ast
High-dose recombinant tumor ne ...... imbs for melanoma and sarcoma.
@en
type
label
High-dose recombinant tumor ne ...... imbs for melanoma and sarcoma.
@ast
High-dose recombinant tumor ne ...... imbs for melanoma and sarcoma.
@en
prefLabel
High-dose recombinant tumor ne ...... imbs for melanoma and sarcoma.
@ast
High-dose recombinant tumor ne ...... imbs for melanoma and sarcoma.
@en
P2093
P356
P1476
High-dose recombinant tumor ne ...... imbs for melanoma and sarcoma.
@en
P2093
F J Lejeune
J J Delmotte
P Ewalenko
P356
10.1200/JCO.1992.10.1.52
P407
P577
1992-01-01T00:00:00Z